​

Bristol-Myers Squibb (BMY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BMY Stock Forecast

Bristol-Myers Squibb (BMY) stock forecast, based on 41 Wall Street analysts, predicts a 12-month average price target of $62.73, with a high of $75.00 and a low of $40.00. This represents a 6.41% increase from the last price of $58.95.

$40 $47 $54 $61 $68 $75 High: $75 Avg: $62.73 Low: $40 Last Closed Price: $58.95

BMY Stock Rating

Bristol-Myers Squibb stock's rating consensus is Hold, based on 41 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (46.34%), 20 Hold (48.78%), 2 Sell (4.88%), and 0 Strong Sell (0.00%).

Hold
Total 41 2 20 19 0 Strong Sell Sell Hold Buy Strong Buy

BMY Price Target Upside V Benchmarks

TypeNameUpside
StockBristol-Myers Squibb6.41%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks1.85%

Price Target Trends

1M3M12M
# Anlaysts41120
Avg Price Target$70.00$63.91$61.60
Last Closing Price$58.95$58.95$58.95
Upside/Downside18.74%8.41%4.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2646181-29
Feb, 2635171-26
Jan, 2634181-26
Dec, 2533201-27
Nov, 2533191-26
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 06, 2026Michael YeeUBS$70.00$59.7917.08%18.74%
Feb 24, 2026Trung HuynhRBC Capital$60.00$61.60-2.60%1.78%
Feb 23, 2026Piper Sandler$75.00$60.6623.64%27.23%
Feb 19, 2026Barclays$75.00$60.3024.38%27.23%
Feb 06, 2026Terence FlynnMorgan Stanley$40.00$61.86-35.34%-32.15%
Feb 06, 2026Guggenheim$72.00$59.5220.97%22.14%
Feb 06, 2026Mohit BansalWells Fargo$60.00$59.520.81%1.78%
Jan 28, 2026Piper Sandler$66.00$55.5618.79%11.96%
Jan 13, 2026David RisingerLeerink Partners$60.00$56.396.40%1.78%
Jan 09, 2026Louise ChenScotiabank$60.00$55.877.39%1.78%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 06, 2026UBSBuyBuyhold
Feb 24, 2026RBC CapitalSector Performinitialise
Feb 23, 2026Piper SandlerOverweightOverweighthold
Feb 19, 2026BarclaysUnderweightOverweightinitialise
Feb 06, 2026Morgan StanleyUnderweightUnderweighthold
Feb 06, 2026GuggenheimBuyBuyhold
Feb 06, 2026Wells FargoOutperformOutperformhold
Jan 28, 2026Piper SandlerOverweightOverweighthold
Jan 27, 2026CitigroupNeutralNeutralhold
Jan 09, 2026ScotiabankSector PerformSector Performhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.15$2.97$3.88$-4.41$3.46---
Avg Forecast$7.47$7.39$7.38$0.91$6.94$6.25$6.28$6.16
High Forecast$7.63$7.58$7.56$1.07$7.29$7.79$7.59$6.39
Low Forecast$7.32$7.13$7.17$0.84$6.44$3.12$3.73$5.97
Surprise %-57.83%-59.81%-47.43%-584.62%-50.14%---

Revenue Forecast

$41B $42B $44B $45B $47B $49B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$46.38B$46.16B$45.01B$48.30B$48.19B---
Avg Forecast$46.46B$45.92B$44.71B$47.50B$46.46B$43.89B$44.24B$41.51B
High Forecast$47.22B$46.86B$45.03B$47.73B$47.75B$43.94B$44.28B$42.71B
Low Forecast$45.74B$44.68B$44.30B$47.42B$45.58B$43.84B$44.20B$40.55B
Surprise %-0.15%0.52%0.66%1.68%3.72%---

Net Income Forecast

$-10B $-4B $2B $8B $14B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.99B$6.33B$8.03B$-8.95B$7.05B---
Avg Forecast$6.97B$6.77B$8.03B$1.99B$14.27B$9.63B$9.71B$12.80B
High Forecast$8.36B$8.13B$9.63B$2.23B$15.15B$16.19B$15.76B$13.28B
Low Forecast$5.58B$5.42B$6.42B$1.75B$13.39B$6.48B$7.75B$12.42B
Surprise %0.34%-6.56%--549.66%-50.56%---

BMY Forecast FAQ

Is Bristol-Myers Squibb stock a buy?

Bristol-Myers Squibb stock has a consensus rating of Hold, based on 41 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 20 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Bristol-Myers Squibb is a neutral investment for most analysts.

What is Bristol-Myers Squibb's price target?

Bristol-Myers Squibb's price target, set by 41 Wall Street analysts, averages $62.73 over the next 12 months. The price target range spans from $40 at the low end to $75 at the high end, suggesting a potential 6.41% change from the previous closing price of $58.95.

How does Bristol-Myers Squibb stock forecast compare to its benchmarks?

Bristol-Myers Squibb's stock forecast shows a 6.41% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (1.85%).

What is the breakdown of analyst ratings for Bristol-Myers Squibb over the past three months?

  • March 2026: 13.79% Strong Buy, 20.69% Buy, 62.07% Hold, 3.45% Sell, 0% Strong Sell.
  • February 2026: 11.54% Strong Buy, 19.23% Buy, 65.38% Hold, 3.85% Sell, 0% Strong Sell.
  • January 2026: 11.54% Strong Buy, 15.38% Buy, 69.23% Hold, 3.85% Sell, 0% Strong Sell.

What is Bristol-Myers Squibb’s EPS forecast?

Bristol-Myers Squibb's average annual EPS forecast for its fiscal year ending in December 2026 is $6.25, marking a 80.64% increase from the reported $3.46 in 2025. Estimates for the following years are $6.28 in 2027, and $6.16 in 2028.

What is Bristol-Myers Squibb’s revenue forecast?

Bristol-Myers Squibb's average annual revenue forecast for its fiscal year ending in December 2026 is $43.89B, reflecting a -8.93% decrease from the reported $48.19B in 2025. The forecast for 2027 is $44.24B, and $41.51B for 2028.

What is Bristol-Myers Squibb’s net income forecast?

Bristol-Myers Squibb's net income forecast for the fiscal year ending in December 2026 stands at $9.63B, representing an 36.53% increase from the reported $7.05B in 2025. Projections indicate $9.71B in 2027, and $12.8B in 2028.